Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 4/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | VEGFA | P15692 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.34 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 2/20 | 0.32 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29237584 | 0.92 | EPAS1 (0.41) | EPAS1DRD1VEGFASLC22A12BRD4 | |
| SCHEMBL30967799 | 0.92 | EPAS1 (0.41) | EPAS1DRD1VEGFASLC22A12BRD4 | |
| SCHEMBL29338274 | 0.87 | SLC22A12 (0.38) | EPAS1DRD1VEGFASLC22A12BRD4 | |
| SCHEMBL30285554 | 0.87 | SLC22A12 (0.38) | EPAS1DRD1VEGFASLC22A12BRD4 | |
| SCHEMBL31111034 | 0.84 | EPAS1 (0.39) | EPAS1VEGFASLC22A12BRD4AR | |
| SCHEMBL30938241 | 0.81 | DRD1 (0.41) | EPAS1DRD1ARPRKCQHAO1 | |
| SCHEMBL27275534 | 0.81 | DRD1 (0.41) | EPAS1DRD1ARPRKCQHAO1 | |
| SCHEMBL27382323 | 0.81 | DRD1 (0.40) | EPAS1DRD1VEGFASLC22A12AR | |
| SCHEMBL31108580 | 0.81 | PRKCQ (0.36) | EPAS1DRD1VEGFASLC22A12AR | |
| SCHEMBL27266377 | 0.81 | PRKCQ (0.36) | EPAS1DRD1VEGFASLC22A12AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | EPAS1 2305/4885DRD1 1043/4885VEGFA 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.